

- with 1–36 months follow-up. *Radiology* 1993; 188:381–387.
40. Whyman MR, Fowkes FG, Kerracher EM, et al. Randomised controlled trial of percutaneous transluminal angioplasty for intermittent claudication. *Eur J Vasc Endovasc Surg* 1996; 12:167–172.
  41. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. *Radiology* 1997; 204:87–96.
  42. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing long-term success. *Circulation* 1991; 83:170–180.
  43. Hunink MG, Wong JB, Donaldson MC, Meyerovitz MF, de Vries J, Harrington DP. Revascularization for femoropopliteal disease. A decision and cost-effectiveness analysis. *JAMA* 1995; 274:165–171.
  44. Stonebridge PA, Naidu S, Colgan MP, Moore DJ, Shanik DG, McCollum PT. Tibial and peroneal artery bypasses using polytetrafluoroethylene (PTFE) with an interposition vein cuff. *J R Coll Surg Edinb* 2000; 45:17–20.
  45. Mannick JA, Whittemore AD, Donaldson MC. Clinical and anatomic considerations for surgery in tibial disease and the results of surgery. *Circulation* 1991; 83:181–185.
  46. Verhelst R, Bruneau M, Nicolas AL, et al. Popliteal-to-distal bypass grafts for limb salvage. *Ann Vasc Surg* 1997; 11:505–509.
  47. Faries PL, Arora S, Pomposelli FB Jr., et al. The use of arm vein in lower-extremity revascularization: results of 520 procedures performed in eight years. *J Vasc Surg* 2000; 31:50–59.
  48. Wolfe KD, Bruijnen H, Reeps C, et al. Tibioperoneal arterial lesions and critical foot ischaemia: successful management by the use of short vein grafts and percutaneous transluminal angioplasty. *Vasa* 2000; 29:207–214.
  49. Eagle KA, Brundage BH, Chaitman BR, et al. Guidelines for perioperative cardiovascular evaluation for noncardiac surgery. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery. *Circulation* 1996; 93:1278–1317.
  50. Mann MJ. Gene therapy for peripheral arterial disease. *Mol Med Today* 2000; 6:285–291.
  51. Chawla PS, Keelan MH, Kipshidze N. Angiogenesis for the treatment of vascular diseases. *Int Angiol* 1999; 18:185–192.
  52. Baumgartner I, Isner JM. Gene therapy for peripheral vascular disease. *Isr Med Assoc J* 2000; 2:27–32.
  53. Schratzberger P, Schratzberger G, Silver M, et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. *Nat Med* 2000; 6:405–413.
  54. Isner JM. Manipulating angiogenesis against vascular disease. *Hosp Pract* 1999; 34:69–80.
  55. Kalka C, Takahashi T, Masuda H, Asahara T, Isner JM. Vascular endothelial factor (VEGF): therapeutic angiogenesis and vasculogenesis in the treatment of cardiovascular disease. *Med Klin* 1999; 94:193–201.
  56. Rivard A, Silver M, Chen D, et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. *Am J Pathol* 1999; 154:355–363.
  57. Isner JM, Walsh K, Symes J, et al. Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. *Hum Gene Ther* 1996; 7:959–988.
  58. Isner JM, Walsh K, Symes J, et al. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. *Circulation* 1995; 91:2687–2692.
  59. Spittell PC. Peripheral vascular disease. In: Murphy J, editor. *Mayo Clinic cardiology review*. 2nd ed. Philadelphia: Lippincott Williams and Wilkins, 2000:1013–1024.
  60. Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of lower limb peripheral arterial occlusion—a consensus document. *Am J Cardiol* 1998; 81:207–218.

ADDRESS: Debabrata Mukherjee, MD, Director, Peripheral Vascular Interventions, Division of Cardiology, 1500 East Medical Center Drive, University of Michigan, Ann Arbor, Michigan 48109-0022; e-mail dmukherjee@pol.net.

## Illicit drug use

(JUNE 2001)

**TO THE EDITOR:** In my recent article, “It’s a rave new world: Rave culture and illicit drug use in the young,”<sup>1</sup> I would like to credit my colleague, Dr. Karen S. Vargo, for leading me to the title and for finding the information regarding raves in Ohio and a rave website. I apologize for this oversight. I would also like to thank Dr. Pierre Paul Tellier of Montreal for sharing his expertise on this topic and for sparking my interest in the first place.

ELLEN S. ROME, MD, MPH  
Head, Section  
of Adolescent Medicine  
Cleveland Clinic

### REFERENCES

1. Rome ES. It’s a rave new world: Rave culture and illicit drug use in the young. *Cleve Clin J Med* 2001; 68:541–550.

## Copyright Compliance and Bulk Reprints

Permission to reproduce articles from the *Cleveland Clinic Journal of Medicine* may be obtained from:

Copyright Clearance Center  
1-800-982-3887, ext. 2862  
marketing@copyright.com  
www.copyright.com

Bulk reprints of articles may be ordered directly from:  
*Cleveland Clinic Journal of Medicine*  
tel 216-444-2661  
fax 216-444-9385  
ccjm@ccf.org